Asceneuron is looking to rival Eli Lilly and Biogen in a new class of oral drugs which block the build-up of toxic tau in Alzheimer’s disease, and has raised $100m to further its plans.
Investors Back Asceneuron To Rival Lilly In Alzheimer’s Oral Drug Class
The Switzerland-based company is ready to begin a Phase II study with a novel OGA inhibitor after raising $100m from a consortium of investors.
More from Business
More from Scrip
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
• By
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.